RKDA Company Profile and Key Details

RKDA has shown weak momentum, losing -40.38% over the past week and -35.48% over the past quarter, though year-to-date performance is down -62.84%. Short-term trend indicators are bullishly aligned (SMA20 -37.23%, SMA50 -40.54%, SMA200 -43.4%). The stock’s 14-day RSI is 18.56 (weak momentum), while the ATR of 0.28 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -67.21% below its high and over -13.05% above its low. Average 10-day trading volume of 33.64 thousand shares is below the 3-month average of 471.55 thousand, indicating normal recent market interest.

Arcadia Biosciences, Inc. generated EPS of -$3.71 over the past year. Five-year average earnings growth is 50.91%. The latest quarter delivered EPS of $0.63. The next quarter is forecast at $nan. Next year's EPS is expected at $40.93. Arcadia Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended November 07, 2025, missed forecasts by -216.67%. The prior quarter beat by -102.53%. Over the last six quarters, Apple has recorded several small beats. These include -49.68% in August 13, 2024.

Arcadia Biosciences, Inc. has 1.37 million shares outstanding. The public float is 1.36 million shares, elevated short interest at 1.52% of float. This equals 20.62 thousand shares. The short ratio is 1.47 days. Institutional investors hold 4.37% of the float. Insiders own 0.82%. Mandala Agribusiness Co-Investments I Ltd holds 9.08 million shares, Shupp Darby E has 1.16 million shares and BISHOP TERRI C has 1.16 million shares.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) closed at $2.20 USD, losing -$0.40 (-15.38%) from the previous close of $2.60. The stock is currently trading near its 52-week low $2.20 and $6.71. With a market capitalization of about $3.01 million, Arcadia Biosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.48). Key stats such as the average daily volume over the past year has been around 555.66 thousand shares, volume is running light vs its 52-week average. Headquartered in Davis, CA, Arcadia Biosciences, Inc. operates in the Basic Materials sector and the Agricultural Inputs industry. Led by CEO Thomas J. Schaefer, the company employs approximately 9 people and listed since May 15, 2015. Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States.

Arcadia Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.24. This means the shares are trading below this model’s fair value.

Arcadia Biosciences, Inc. trades at a P/E ratio of -0.47, slightly below the S&P 500 average, with a price-to-sales ratio of 0.66 and a price-to-book ratio of 0.78 suggesting the stock is closer to book value. The P/FCF stands at -0.47, also above market averages.

Our AI price prediction model suggests that Arcadia Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.91%, with price expected at $2.07 by January 12, 2026, within a range of $1.92 to $2.22 3-Month Outlook: Projected fall of -75.45%, reaching $0.54 by March 26, 2026, with a range of $0.38 to $0.69. 1-Year Outlook: Projected gain of 240.45%, with price at $7.49 by December 29, 2026, within a range of $2.17 to $9.98.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) shares are down -62.84% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Arcadia Biosciences, Inc. trading at a premium to the broader market with a P/E of -0.47. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.12, suggesting 405.45% upside. Our AI forecast model points to short-term weakness (-5.91% over two weeks), a medium-term fall (-75.45% over three months), and a longer-term gain (240.45% over one year), with expected trading ranges indicating moderate volatility.